Opendata, web and dolomites

DesignerAntibiotics

Towards the prevention of aminoglycoside antibiotic-related deafness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DesignerAntibiotics project word cloud

Explore the words cloud of the DesignerAntibiotics project. It provides you a very rough idea of what is the project "DesignerAntibiotics" about.

die    chemically    imperial    million    london    infancy    rare    maintaining    vitro    author    despite    acquisition    economically    bacteria    threatening    caused    mitochondrial    phd    journal    antimicrobials    genetics    cells    safer    shown    resistance    ear    group    suffer    1555a    modify    ototoxicity    stanford    ucl    models    mutation    guided    distinction    effect    college    15    impairment    language    crystallography    publication    annually    infections    generation    masters    published    murine    patented    exposed    billion    children    aminoglycosides    patient    inner    urgent    antibacterial    antibiotics    incidence    treatment    resistant    critically    22    university    20    potency    hearing    biobank    patients    investigation    78    deaf    biology    dna    molecular    first    data    life    profoundly    class    human    structural    impedes    compounds    clinical    amounts    profound    25    diminish    annual    irreversible    care    candidate    occurs    drawback    damage    limits    neonatal    100    intensive    drug    aminoglycoside    incurred    gt   

Project "DesignerAntibiotics" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 251˙857 €
 EC max contribution 251˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-02-13   to  2020-02-12

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 251˙857.00
2    BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY US (STANFORD) partner 0.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf.

Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DESIGNERANTIBIOTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DESIGNERANTIBIOTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

KiT-FIG (2019)

Kidney Transplantation - Functional ImmunoGenomics

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More